[Metergoline in hyperprolactinemic breast cancer: a phase II study].
The prolactin release inhibiting action of the dopamine receptor agonist metergoline was investigated in 16 patients with metastatic breast cancer associated with hyperprolactinemia. At a daily dose of 12 mg p.o. for 30 days, the drug was highly effective in lowering prolactin levels (day 0: 1076 +/- 171, day 29: 249 +/- 46 mU/l) in these patients. Starting treatment with 4 mg/day, the side effects of the treatment were mild, including dizziness and nausea.
D001943:Breast Neoplasms / Q000097:blood / Q000188:drug therapy*; D004341:Drug Evaluation; D004873:Ergolines / Q000627:therapeutic use*; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D006966:Hyperprolactinemia / Q000188:drug therapy*; D007986:Luteinizing Hormone / Q000097:blood; D008711:Metergoline / Q000627:therapeutic use*; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011379:Prognosis; D011388:Prolactin / Q000097:blood*; D011954:Receptors, Dopamine / Q000187:drug effects; D013972:Thyrotropin / Q000097:blood
D004873:Ergolines; D011954:Receptors, Dopamine; D008711:Metergoline; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D013972:Thyrotropin
Metergolin beim hyperprolaktinämischen Mammakarzinom: Eine Phase-II-Studie.